Cargando…

Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics

Extracellular matrix (ECM) plays a critical role in maintaining elasticity in cardiac tissues. Elasticity is required in the heart for properly pumping blood to the whole body. Dysregulated ECM remodeling causes fibrosis in the cardiac tissues. Cardiac fibrosis leads to stiffness in the heart tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarohi, Vivek, Chakraborty, Sanchari, Basak, Trayambak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722982/
https://www.ncbi.nlm.nih.gov/pubmed/36483540
http://dx.doi.org/10.3389/fmolb.2022.1030226
_version_ 1784844077769949184
author Sarohi, Vivek
Chakraborty, Sanchari
Basak, Trayambak
author_facet Sarohi, Vivek
Chakraborty, Sanchari
Basak, Trayambak
author_sort Sarohi, Vivek
collection PubMed
description Extracellular matrix (ECM) plays a critical role in maintaining elasticity in cardiac tissues. Elasticity is required in the heart for properly pumping blood to the whole body. Dysregulated ECM remodeling causes fibrosis in the cardiac tissues. Cardiac fibrosis leads to stiffness in the heart tissues, resulting in heart failure. During cardiac fibrosis, ECM proteins get excessively deposited in the cardiac tissues. In the ECM, cardiac fibroblast proliferates into myofibroblast upon various kinds of stimulations. Fibroblast activation (myofibroblast) contributes majorly toward cardiac fibrosis. Other than cardiac fibroblasts, cardiomyocytes, epithelial/endothelial cells, and immune system cells can also contribute to cardiac fibrosis. Alteration in the expression of the ECM core and ECM-modifier proteins causes different types of cardiac fibrosis. These different components of ECM culminated into different pathways inducing transdifferentiation of cardiac fibroblast into myofibroblast. In this review, we summarize the role of different ECM components during cardiac fibrosis progression leading to heart failure. Furthermore, we highlight the importance of applying mass-spectrometry-based proteomics to understand the key changes occurring in the ECM during fibrotic progression. Next-gen proteomics studies will broaden the potential to identify key targets to combat cardiac fibrosis in order to achieve precise medicine-development in the future.
format Online
Article
Text
id pubmed-9722982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97229822022-12-07 Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics Sarohi, Vivek Chakraborty, Sanchari Basak, Trayambak Front Mol Biosci Molecular Biosciences Extracellular matrix (ECM) plays a critical role in maintaining elasticity in cardiac tissues. Elasticity is required in the heart for properly pumping blood to the whole body. Dysregulated ECM remodeling causes fibrosis in the cardiac tissues. Cardiac fibrosis leads to stiffness in the heart tissues, resulting in heart failure. During cardiac fibrosis, ECM proteins get excessively deposited in the cardiac tissues. In the ECM, cardiac fibroblast proliferates into myofibroblast upon various kinds of stimulations. Fibroblast activation (myofibroblast) contributes majorly toward cardiac fibrosis. Other than cardiac fibroblasts, cardiomyocytes, epithelial/endothelial cells, and immune system cells can also contribute to cardiac fibrosis. Alteration in the expression of the ECM core and ECM-modifier proteins causes different types of cardiac fibrosis. These different components of ECM culminated into different pathways inducing transdifferentiation of cardiac fibroblast into myofibroblast. In this review, we summarize the role of different ECM components during cardiac fibrosis progression leading to heart failure. Furthermore, we highlight the importance of applying mass-spectrometry-based proteomics to understand the key changes occurring in the ECM during fibrotic progression. Next-gen proteomics studies will broaden the potential to identify key targets to combat cardiac fibrosis in order to achieve precise medicine-development in the future. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9722982/ /pubmed/36483540 http://dx.doi.org/10.3389/fmolb.2022.1030226 Text en Copyright © 2022 Sarohi, Chakraborty and Basak. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Sarohi, Vivek
Chakraborty, Sanchari
Basak, Trayambak
Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title_full Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title_fullStr Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title_full_unstemmed Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title_short Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
title_sort exploring the cardiac ecm during fibrosis: a new era with next-gen proteomics
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722982/
https://www.ncbi.nlm.nih.gov/pubmed/36483540
http://dx.doi.org/10.3389/fmolb.2022.1030226
work_keys_str_mv AT sarohivivek exploringthecardiacecmduringfibrosisanewerawithnextgenproteomics
AT chakrabortysanchari exploringthecardiacecmduringfibrosisanewerawithnextgenproteomics
AT basaktrayambak exploringthecardiacecmduringfibrosisanewerawithnextgenproteomics